BioCentury
ARTICLE | Financial News

Gadeta raises EUR 7M for T cell therapies

March 30, 2016 1:31 AM UTC

Gadeta B.V. (Utrecht, the Netherlands) raised EUR 7 million ($7.8 million) in a series A round led by Baxalta Ventures and Medicxi Ventures. Gadeta's founders, management and Utrecht Holdings also participated.

Gadeta is developing optimized gamma delta T cell receptor ( TCR) therapeutics it calls TEGs based on its Combinatorial T Cell Receptor Exchange (CTE) technology platform. It said the therapeutics have an "enhanced anti-cancer reactivity" based on sensing metabolic changes in cancer cells selectively. ...